KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Equity Average (2016 - 2025)

Regeneron Pharmaceuticals has reported Equity Average over the past 17 years, most recently at $31.1 billion for Q4 2025.

  • Quarterly results put Equity Average at $31.1 billion for Q4 2025, up 6.02% from a year ago — trailing twelve months through Dec 2025 was $31.1 billion (up 6.02% YoY), and the annual figure for FY2025 was $30.3 billion, up 9.55%.
  • Equity Average for Q4 2025 was $31.1 billion at Regeneron Pharmaceuticals, up from $30.4 billion in the prior quarter.
  • Over the last five years, Equity Average for REGN hit a ceiling of $31.1 billion in Q4 2025 and a floor of $11.5 billion in Q1 2021.
  • Median Equity Average over the past 5 years was $24.1 billion (2023), compared with a mean of $23.6 billion.
  • Peak annual rise in Equity Average hit 70.33% in 2021, while the deepest fall reached 0.95% in 2021.
  • Regeneron Pharmaceuticals' Equity Average stood at $18.0 billion in 2021, then increased by 22.42% to $22.1 billion in 2022, then rose by 15.36% to $25.4 billion in 2023, then rose by 15.33% to $29.3 billion in 2024, then increased by 6.02% to $31.1 billion in 2025.
  • The last three reported values for Equity Average were $31.1 billion (Q4 2025), $30.4 billion (Q3 2025), and $29.7 billion (Q2 2025) per Business Quant data.